Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. - Wikidata - awgldk - TriplyDB

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

http://www.wikidata.org/entity/Q35163538

about

Pericyte-targeting drug delivery and tissue engineering Anti-angiogenic alternatives to VEGF blockade Targeting angiogenesis in gynecologic cancers A systems biology view of blood vessel growth and remodelling Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B PDGF: the nuts and bolts of signalling toolbox.SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Src family kinases and paclitaxel sensitivity.Clinical utility of targeted treatments in the management of epithelial ovarian cancer.Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.Molecular aptamers for drug delivery.Novel targets for VEGF-independent anti-angiogenic drugs.Targeting PDGF pathway in pulmonary arterial hypertension.Heparan sulfate in angiogenesis: a target for therapy.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.The adaptive stroma joining the antiangiogenic resistance front.Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells.Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.

P2860

Q26745598-E0A7887C-0EF2-433E-9A9B-142FFC4126C8 Q26775947-6EDFC6B4-2D0E-4ABC-93AA-2262C608BF86 Q26824766-692593DE-32B6-4AC8-AB60-C3CD76CD42A2 Q27003945-4258EFD9-923D-4C07-8AC4-A48D9614D7AB Q27016629-72BC4043-749B-40E6-8165-FB77932A966E Q30250273-43D5D2EF-647F-4A11-BAB8-B40CE905A114 Q33638726-EBDD1DC8-16F7-4639-A44C-A0909BDF8CD5 Q33745022-C7B5BBDF-C8A0-4CFD-8075-77E813A61FF7 Q33922852-6E532593-DE1C-47FE-B308-14DFFF556D86 Q33965086-97BC20A5-3474-46B0-9A20-1419F9E1BB4B Q34017318-41DA37BB-F66E-467D-88E8-E696C6E55818 Q34433040-A7EB79EA-8597-4BCF-B5C1-161962711FAA Q35214722-7D02FF2E-46D6-4E73-901B-37A29E8D296A Q36171268-14A0F05C-81B6-4EA6-8BDC-6AF09A3E5670 Q36284948-DD5EB6DA-F543-4163-9A21-45EA0BAF0397 Q36824048-1EB40C81-B57C-44E4-A133-0E86BF02181E Q37570010-01891BB2-415A-4A55-918D-E70C64AD59DB Q37723067-A69F9248-968C-4E23-AEBD-FC4089D9F951 Q37912756-DB3D3DDD-AF2E-4112-8AC7-5749B2BE1DF7 Q37984612-A5BA358C-5811-42FD-89A3-CE1EED81808D Q38038222-62F0AD5A-D7AD-49E4-A706-1D5494249C5E Q38154506-5F70C5C7-A5F1-4D48-ACC4-AB9A2A2D1283 Q38498207-620DAF38-94A9-4585-9536-17147CA79FEE Q38682486-C724B5B6-0D45-421B-B3CF-E2F1165EAD42 Q38757723-29300EE0-7ABC-4A56-B226-18A51696605C Q38941996-597D3B23-A7F4-4A35-AEAE-EE354DCE93AE Q39051468-FA848ED8-E679-4235-8AC3-0F4D0DD2C452 Q39403862-D287AF72-4FC8-42DB-84DC-2A431E8EA6D4 Q42125857-D112048D-59E0-4070-AAB8-EBA8A68F0AC5 Q49857214-E8F52216-892C-477A-BB89-8911631DD3F7 Q54458131-AA0E99CA-81C7-448F-A1EB-C815BD5D569F

P2860

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

http://www.wikidata.org/entity/Q35163538

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@ast

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@en

type

label

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@ast

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@en

prefLabel

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@ast

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@en

P1433

Q35163538-C200B1E4-E0DF-4F45-8936-DF0E825B2B30

P1476

Q35163538-CFA44E1C-8621-41CA-A61D-A697C0BE1B6E

P2093

Q35163538-0560C0C9-9847-42C4-AAFF-94EE60C98382

Q35163538-091AA492-7D49-4850-B082-1E8D5CCEC5CB

Q35163538-13D93578-ECAD-4CDC-98D3-410C04741B25

Q35163538-2ED6B479-22B2-49C7-AE79-EFD54A6370EE

Q35163538-443600A8-E5D1-437E-83CE-C5A1805761F3

Q35163538-5389C01D-A5F3-4E84-AC80-24A5A65729D1

Q35163538-9C08E5F6-0BA3-4740-9607-34707BDCC31C

Q35163538-A48D6199-D4E7-4FBF-AA95-09334220FD24

Q35163538-A8EC94BD-A2FD-417D-81A6-97CB8108C606

Q35163538-C965E05B-07BF-4403-ABE8-61128D29A9C4

P2860

Q35163538-08C27DAE-323F-4CD9-AAD4-74BCD93FB103

Q35163538-0AF5DEF7-C367-4041-B1E6-F1FD75314BF3

Q35163538-0BAD800A-FE9F-48C1-8C99-DFA0E9FD77EA

Q35163538-0C03A140-BFFA-4E37-9A75-DBB57CA95B6A

Q35163538-0FB6BEBD-012B-40A2-A48F-7E63103DB6B3

Q35163538-20C1DAC0-45F0-4CB7-998C-8B4220C7CACD

Q35163538-30138339-896C-45BE-946E-706B13F3F8C4

Q35163538-49C1ADB9-53CA-4159-A651-8806F131BB9D

Q35163538-5960101A-5BD1-46E7-A277-DB0D3E5DE416

Q35163538-5DAF55D7-AA3C-4228-AD6C-2E7DD2939767

P304

Q35163538-3920C0B9-6784-4CB5-9047-F6BB1ACFA3C1

P31

Q35163538-F947C63D-D328-4D0B-A14E-432C9C4ECFF1

P356

Q35163538-3133356B-1CE1-472F-8056-D2D0B50D9AA4

P433

Q35163538-0ED50024-847C-42B3-A1FC-C25B46094594

P478

Q35163538-41398BDF-F045-4DC9-B724-7E0AD3F52899

P577

Q35163538-BF75748D-7967-45A6-85AE-131C45D3FA27

P5875

Q35163538-251BD19A-24F9-4874-A96C-8B17624E75E6

P698

Q35163538-A09B936D-1213-480A-9F98-5BE50B1A67A2

P921

Q35163538-B009FE65-132D-4E47-AA20-BCA59CD1DD07

P932

Q35163538-72B5672E-88EB-4FC0-87B1-B8B4E7F31F21

P356

P1433

Cancer Biology and Therapy

P1476

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

@en

P2093

Alpa M Nick

http://www.w3.org/2001/XMLSchema#string

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

Chunhua Lu

http://www.w3.org/2001/XMLSchema#string

Guillermo N Armaiz-Pena

http://www.w3.org/2001/XMLSchema#string

Julie K Allen

http://www.w3.org/2001/XMLSchema#string

Lingegowda S Mangala

http://www.w3.org/2001/XMLSchema#string

Mian M K Shahzad

http://www.w3.org/2001/XMLSchema#string

Myrthala Moreno-Smith

http://www.w3.org/2001/XMLSchema#string

Nicholas B Jennings

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content

Pericytes in the microvasculature.

Developmental roles of platelet-derived growth factors.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

The role of angiogenesis in tumor growth.

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

P304

176-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.9.3.10635

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40687269

http://www.w3.org/2001/XMLSchema#string

P698

20009575

http://www.w3.org/2001/XMLSchema#string

P921

P932

3155813

http://www.w3.org/2001/XMLSchema#string